{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P15056",
      "entity_text" : "B-Raf",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04458",
      "entity_text" : "multi-kinase inhibitor",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "At present, sorafenib, a multi-kinase inhibitor that inhibits Raf-1, B-Raf, vascular endothelial growth factor receptors, and platelet growth factor receptor, is the only systemic therapy that has demonstrated an overall survival benefit in patients with advanced HCC XREF_BIBR.",
  "reading_complete" : "2020-08-02T12:36:39Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T12:35:17Z",
  "trigger" : "inhibits",
  "evidence" : [ "multi-kinase inhibitor that inhibits Raf-1, B-Raf" ],
  "pmc_id" : "5327636",
  "score" : 0
}